🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsOral GLP-1 AgonistsOral semaglutide bioavailability optimization — 12 month update Page 8

Oral semaglutide bioavailability optimization — 12 month update

jim_asheville Wed, Feb 7, 2024 at 4:58 PM 58 replies 3,516 viewsPage 8 of 12
DataDave
Senior Member
1,678
8,901
Apr 2024
Washington
Online
Mar 23, 2024 at 5:59 PM#36
EndoResFellow said:
It helps to ask what evidence would change your mind before you look at any.

This matches mine closely enough to be worth saying so out loud.

Last edited: Mar 23, 2024 at 6:59 PM
8 8VendorMark, COA_Karl, MikeFit_NJ and 5 others
Reply Quote Save Share Report
matt_MKE
Member
312
1,345
Sep 2024
Milwaukee, WI
Mar 26, 2024 at 6:04 AM#37
EndoResFellow said:
It helps to ask what evidence would change your mind before you look at any.

Coming at EndoResFellow’s question from a different direction. Steady state is the thing most people miss. The terminal half-life is about a week, so every dose step takes four to five weeks to fully express itself. Judging a step at day ten is judging the ascent, not the plateau, and it is the single commonest reason people escalate before they needed to.

7 7Dr.EndoEP, GraceAZ_72, carl_compliance and 4 others
Reply Quote Save Share Report
quinn_sf
Member
489
2,123
Jun 2024
San Francisco, CA
Mar 28, 2024 at 6:11 PM#38

One concrete data point for the thread. Worth stating the units and the reference range whenever you post a number here. A large fraction of the apparent disagreement in these threads is two people using different units and both being right.

6 6mona_PHX, andrew_nyc, Dr.EndoEP and 3 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
mia_MS2
New Member
8
23
Jun 2026
Ann Arbor, MI
Mar 31, 2024 at 6:19 AM#39

Following on from EndoResFellow — and this may be the naive question:

What did you change at the same time, and can you separate the two now?

5 5steve_okc, dave_SLC, FDA_TrackerJim and 2 others
Reply Quote Save Share Report
COA_Karl
Senior Member
2,123
8,901
Jan 2024
Pennsylvania
Apr 2, 2024 at 6:29 PM#40
quinn_sf said:
Worth stating the units and the reference range whenever you post a number here.

I read this differently from quinn_sf, on substance rather than tone. Filing an objection on the n=1 problem. Personal experience is genuine evidence about one person and very weak evidence about anybody else, and this thread keeps promoting the first into the second.

Ask again with the specifics and you will get a better answer than this one.

Last edited: Apr 2, 2024 at 7:29 PM
33 8LindaRN_retired, tommy_boulder, hyun_seoul and 30 others
Reply Quote Save Share Report
167891012

Similar Threads

Orforglipron Phase 3 ATTAIN-1 topline — oral non-peptide GLP-116 replies
Oral semaglutide 50mg (Rybelsus HD) — OASIS program results12 replies
Danuglipron BID dosing — Pfizer oral GLP-1 update7 replies
Oral vs injectable GLP-1: bioavailability and efficacy comparison5 replies
Orforglipron food interaction profile — no fasting requirement15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register